Of note, in a study of 57 patients with metastatic colorectal cancer and ERBB2 amplification, despite an overall objective response rate of 32%, none of the 8 patients with amplification without HER2 overexpression responded to trastuzumab and pertuzumab. Here, ERBB2 is linked to metastatic colorectal cancer.